Meeting
2022 ASCO Annual Meeting
Genomic aberrations associated with overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or placebo (PBO) plus androgen deprivation therapy (ADT) in TITAN.
Authors
Neeraj Agarwal
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Neeraj Agarwal , Justin Lucas , Clemente Aguilar-Bonavides , Shibu Thomas , Michael Gormley , Simon Chowdhury , Axel S. Merseburger , Anders Bjartell , Hirotsugu Uemura , Mustafa Özgüroğlu , Sharon McCarthy , Sabine D. Brookman-May , Florence Lefresne , Suneel Mundle , Kim N. Chi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Clinical Trial Registration Number
NCT02489318
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5066)
DOI
10.1200/JCO.2022.40.16_suppl.5066
Abstract #
5066
Poster Bd #
249
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).
First Author: Joaquin Mateo
Poster
2023 ASCO Annual Meeting
Spectrum of germline pathogenic variants among patients with cancer in Mexico.
First Author: Jose Luis Rodriguez Olivares
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh
Poster
2022 ASCO Genitourinary Cancers Symposium
Genomic characterization of patients (pts) with de-novo high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) compared to those without dn-hv-mCSPC.
First Author: Nicolas Sayegh